Navigation Links
GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
Date:11/10/2008

es at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and the GeoVax team.

GeoVax HIV/AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of HIV/AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $15 million IPCAVD grant awarded in late 2007. http://www.geovax.com

Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether; GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be determined to be safe for use in humans, GeoVax's vaccines will be effective in preventing AIDS in humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed, GeoVax can raise the required capital to complete development of its vaccines, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news rele
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 2014 Deep ... Industry” is a professional and in-depth research report ... basic Naltrexone HCL information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:10/30/2014)... 2014 Rancho BioSciences , the ... manually curated public data source TCGA for ... the data is now available for other oncology groups. ... and internal data sources for their Pharma, Government and ... the data that becomes more easily accessible. Rancho ...
(Date:10/30/2014)... York, NY (PRWEB) October 30, 2014 ... plan for its ICH Stability Testing and Package Test ... this investment centers on a dramatic increase in environmental ... volume of stability, storage and aging samples to be ... stage of this major capital expenditure has already taken ...
(Date:10/30/2014)... Oct. 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... that management will present a company overview at the Nomura ... ET in Boston, MA. ... the "Investors & Media" section of the Company,s website, ... website within 48 hours and will be archived for a ...
Breaking Biology Technology:Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Rancho BioSciences Manually Curated TCGA Data Sets Available 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... Oct. 26, 2011 Accuray Incorporated (Nasdaq: ... announced today significant momentum in global adoption of its ... are now in use at leading cancer centers throughout ... image-guided, intensity-modulated radiation therapy (IG-IMRT) for routine radiation therapy ...
... poison from this smorgasbord of recent salmonella outbreaks in ... That,s in 2011 alone, and the list goes on, ... Prevention. But perhaps not for long, thanks to a ... of salmonella bacteria before contaminated food or animals reach ...
... ProteinSimple today announced the launch of the ... Imaging platforms. Bot1 automates analysis of protein aggregates and ... the IBC,s 11th Annual Formulation Strategy for Protein Therapeutics ... Protein therapeutic manufacturers must monitor microscopic particles and ...
Cached Biology Technology:Accuray Announces Rapid Clinical Adoption of TomoDirect™ Treatment Delivery Mode 2Accuray Announces Rapid Clinical Adoption of TomoDirect™ Treatment Delivery Mode 3Accuray Announces Rapid Clinical Adoption of TomoDirect™ Treatment Delivery Mode 4ProteinSimple Automates Aggregation Analysis 2
(Date:10/30/2014)... NY, October 30, 2014—Oligonucleotide-based therapeutics present unique challenges ... cause reproductive and developmental harm. New consensus guidelines ... combined chemical and biological characteristics of these novel ... , a peer-reviewed journal from Mary Ann ... free on the Nucleic Acid Therapeutics ...
(Date:10/30/2014)... | Heidelberg, 30 October 2014 Biological membranes are ... understanding of adsorption of solution ions onto lipid ... Now, a new study provides a quantitative description ... solution ions. Joanna Kotyńska and Zbigniew Figaszewski from ... of a study describing these findings, just published ...
(Date:10/29/2014)... their hair as a consequence of chemotherapy will benefit ... scalp cooling technology that prevents hair loss. , The ... by global scalp cooling manufacturing company, Paxman Coolers, of ... of the University of Huddersfield. , The research will ... a background in the pharmacology of cancer treatment, which ...
Breaking Biology News(10 mins):New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Ion adsorption matter in biology 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2
... Marine Board-ESF published its 13th Position Paper, which presents ... needed to assess the effects of anthropogenic sound upon ... Board Position Paper 13 results from the activities and ... marine mammals convened at the joint European Marine Board ...
... gorgeously-decorated fish which throng Australia,s coral reefs and help earn ... be written in their genes. Of particular importance may ... re-colonise regions of reef devastated by global warming and other ... says Dr Line Bay of the ARC Centre of Excellence ...
... base and,revenues, JERICHO, N.Y., Sept. 29 ... it has executed a non-binding,Letter of Intent with ... controlling interest in Biometric Solutions, Inc. The terms ... Biometric Solutions LLC is a premiere engineering firm, ...
Cached Biology News:Effects of anthropogenic sound on marine mammals -- a research strategy 2Fishy future written in the genes 2Fishy future written in the genes 3bioMETRX, Inc. Signs Deal To Acquire Controlling Interest in Biometric Solutions, LLC 2bioMETRX, Inc. Signs Deal To Acquire Controlling Interest in Biometric Solutions, LLC 3
Pronase Reagent...
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: